Blimey... So - 'Registration grade' ph2 trials are designed to confirm and support swifter regulatory approval as opposed to standard ph2 trials which are much more exploratory in nature. Glad i looked this up.... Registration grade ph2 trials can potentially REPLACE or reduce ph3 requirements...!
I think most missed this info, myself included until tonight....
Appreciate some been here a lot longer than me but it seems AFC have made meaningful progress in the last 9 months or so. Both major JV’s now been running for circa 6 months or more. I’m sure there has been progress and the CEO would want to update the market of that progress as much as possible either before or as part of the results.
Nothing goes up in a straight line, I see no reason why JV partners would want to pull out so IMO from the 8-10p floor we are well positioned for growth over the next 12 mths.
I remember in 2020 when CHF made the monster move from 1.5p to 18-19p. Hitting those levels again would equate to circa 35mill m cap. Not inconceivable for a junior co' should the management team / new investors pivot in a new direction that captivates the market. Lots of recent investment from directors / new investors around this level - it seems they certainly high hopes for the future of Chesterfield.
He said it very clearly in fact during the last 5-10 mins of that interview.
Was a very interesting listen, what Nick doesn’t know about Hydrogen isn’t worth knowing. He is a great asset to the team.
Interview has also got me salivating to hear of the S&P500 partner. Seems like they carried out a high amount of DD prior to selecting AFC as their ‘mobile solution’ cracker partner.